India's Lupin Pharmaceuticals Inc. (500257: Quote,LUPIN: Quote) on Thursday said it won the final approval from U.S. Food and Drugs Administration, or FDA, to market its anti-depressant drug, escitalopram tablets, a generic version of Forest Laboratories' lexapro tablets in the U.S.
In addition, Lupin said it was the only Asian company to achieve the distinction of being the fifth largest generics player in the U.S.
Lupin's Escitalopram Tablets will be used to treat adults and children between 12-17 years and who suffer from major depressive and anxiety disorders in adults.
Click here to receive FREE breaking news email alerts for Lupin Ltd. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org